Value Sense
PODD
Insulet Corporation (PODD)
Last Price$272.70.1%
Market Cap$19.4B
Intrinsic value score
8/10
Great
Intrinsic value
$134.5
DCF value - N/A Relative value - $134.5
Overvalued
50.7%
LTM P/E
46.3x
Peer set median 32.4x
Discount rate
9.7%
PODD
is 50.7% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

PODD Intrinsic value

Key Highlights:
Relative Value vs Current Share Price
As of Mar 03, 2025 PODD Relative Value is $136.4, which is overvalued by 50.0%, compared to current share price of $272.7.
DCF Value vs Current Share Price
As of Mar 03, 2025 PODD DCF Value is N/A, which is undervalued by N/A, compared to current share price of $272.7.
Methodology
Price per share, $
PODD
Intrinsic value$134.5
Overvalued by50.7%
Current share price
272.7
Relative value
136.4
DCF value
not available

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

PODD Historical Intrinsic Value

Crunching data... Almost there!

PODD vs Peer Set: Intrinsic Value Comparison

General

Intrinsic Value

Financials

Company name

Undervaluation/Overvaluation

Revenue growth

EPS growth

Net income margin

Insulet Corporation logo
Insulet CorporationPODD
(50.7%)
30.0%
4,364.6%
12.2%
Median Peer Set
4.1%
72.0%
12.4%
Boston Scientific Corporation logo
Boston Scientific CorporationBSX
(67.4%)
17.6%
16.7%
11.1%
DexCom, Inc. logo
DexCom, Inc.DXCM
(49.8%)
11.3%
(1.4%)
14.3%
Edwards Lifesciences Corporation logo
Edwards Lifesciences CorporationEW
(24.2%)
(9.4%)
202.2%
76.7%
Stryker Corporation logo
Stryker CorporationSYK
(22.7%)
10.2%
(5.8%)
13.2%
STERIS plc logo
STERIS plcSTE
(10.4%)
3.6%
257.9%
7.4%
Align Technology, Inc. logo
Align Technology, Inc.ALGN
8.5%
3.4%
26.0%
11.5%
Medtronic plc logo
Medtronic plcMDT
21.5%
3.6%
(2.1%)
11.4%
Abbott Laboratories logo
Abbott LaboratoriesABT
24.5%
4.6%
134.5%
31.9%
Zimmer Biomet Holdings, Inc. logo
Zimmer Biomet Holdings, Inc.ZBH
72.0%
6.5%
253.2%
13.8%
Koninklijke Philips N.V. logo
Koninklijke Philips N.V.PHG
146.8%
(0.8%)
118.1%
(3.9%)

Explore more intrinsic value tools hub for PODD

Peter Lynch Fair Value
Intrinsic Value
Earnings Power Value
Ben Graham Fair Value
Earnings growth model
DCF value calculator
Discount rate
Peter Lynch charts
Reverse DCF
Relative Value

FAQ

What is Insulet Corporation intrinsic value?

As of Mar 03, 2025, Insulet Corporation Intrinsic Value is $134.5. This suggests it may be overvalued by 50.7% compared to its current price of around $272.7.

What is Insulet Corporation DCF (discounted cash flow) valuation?

As of Mar 03, 2025, Insulet Corporation's Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by N/A to its current price of around $272.7, using a discount rate of 9.7% and terminal growth rate of 3.0%.

Is Insulet Corporation overvalued or undervalued?

Insulet Corporation is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $134.5, compared to a market price of around $272.7. This suggests a potential overvaluation of 50.7%.